METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy combo takes on tough pancreatic cancer
Disease control CompletedThis phase 2 trial tested whether adding an immunotherapy drug called botensilimab to standard chemotherapy could help people with metastatic pancreatic cancer who had already progressed on a common chemo regimen (FOLFIRINOX). The study enrolled 81 participants and compared the c…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for tough pancreatic cancer? drug combo trial shows promise
Disease control CompletedThis study tested a new drug called NIS793 added to standard chemotherapy for people with metastatic pancreatic cancer that has spread. The goal was to see if the combination could help patients live longer by reducing scar tissue in the tumor. About 511 adults with this advanced…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Electric field therapy combined with chemo shows promise for tough pancreatic cancer
Disease control CompletedThis pilot study tested a wearable device that delivers low-intensity electric fields (TTFields) together with immunotherapy (atezolizumab) and two chemotherapy drugs (gemcitabine and nab-paclitaxel) in 84 people with metastatic pancreatic cancer who had not received prior treatm…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: NovoCure Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Tailored chemo doses may help seniors fight pancreatic cancer while staying independent
Disease control CompletedThis study tested a chemotherapy cocktail called FOLFIRINOX in 72 patients aged 70 or older with metastatic pancreatic cancer. The doses were adjusted based on each person's genetics to reduce side effects while still fighting the tumor. The goal was to see if this approach could…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Institut Cancerologie de l'Ouest • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug cocktail targets Hard-to-Treat gut cancers
Disease control CompletedThis study tested a new cancer drug called ERAS-007, given by mouth, together with other targeted therapies in 101 people with advanced colorectal or pancreatic cancers that have certain gene changes. The main goals were to check safety, find the best dose, and see how the drugs …
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo tested for tough pancreatic cancer
Disease control CompletedThis early-phase trial tested whether adding the drug anakinra to standard chemotherapy is safe for people with metastatic pancreatic cancer. Thirteen adults with advanced disease received the combination. The main goal was to check for side effects, not to see if it works.
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo may extend life in tough pancreatic cancer
Disease control CompletedThis study looked at 211 people with advanced pancreatic cancer whose first treatment (FOLFIRINOX) stopped working or caused too many side effects. Researchers compared a two-drug combination (gemcitabine and paclitaxel) against gemcitabine alone to see if the combo helped people…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Experimental antibody combo shows promise against tough cancers
Disease control CompletedThis study tested a new antibody called ICT01 combined with low-dose interleukin-2 (IL-2) in 56 people with advanced solid tumors like colorectal, ovarian, and pancreatic cancer. The goal was to see if the combo is safe and can shrink tumors. Early results suggest it may help con…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: ImCheck Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Vitamin d derivative tested as chemo booster for pancreatic cancer
Disease control CompletedThis small pilot study tested whether adding a vitamin D-like drug called paricalcitol to standard chemotherapy could help people with advanced pancreatic cancer that had stopped responding. 27 patients received chemotherapy first, then paricalcitol was added if their disease sta…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Barts & The London NHS Trust • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New hope for pancreatic cancer? immunotherapy cocktails tested in major trial
Disease control CompletedThis study tested several immunotherapy-based drug combinations in 341 people with metastatic pancreatic cancer. Participants were split into two groups: those who had not yet received treatment and those who had already tried one type of chemotherapy. The goal was to see if thes…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New hope for tough pancreatic cancer? early trial tests immune boosts
Disease control CompletedThis early-phase trial tested different combinations of immunotherapy drugs with standard chemotherapy for people with metastatic pancreatic cancer that had not been treated before. The main goal was to check safety and see if the combinations could shrink tumors or control the d…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Cancer Insight, LLC • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC